Antagonist Protocol in Poor Responders
Information source: Cairo University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Female Infertility Due to Diminished Ovarian Reserve
Intervention: Growth Hormone (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Cairo University Official(s) and/or principal investigator(s): Yomna A Bayoumi, MD, Principal Investigator, Affiliation: Cairo University
Summary
The effect of use of the growth hormone with antagonist protocol on the outcome of the
IVF/ICSI cycles in poor responders.
Clinical Details
Official title: Does the Addition of Growth Hormone to the Invitro Fertilization/ Intracytoplasmic Sperm Injection Antagonist Protocol Improve Outcome in Poor Responders? A Randomized Controlled Trial
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Live birth rate
Secondary outcome: Clinical pregnancy rate
Detailed description:
Two groups of poor responder female patients planned to receive the antagonist IVF/ICSI
protocol are randomized to whether or not to add growth hormone to their protocol.
Eligibility
Minimum age: 20 Years.
Maximum age: 45 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- females fulfilling the criteria of the ESHRE consensus 2011:
- at least two of the following three features must be present:
- dvanced maternal age (≥40 years) or any other risk factor for POR
- previous POR (≤3 oocytes with a conventional stimulation protocol)
- an abnormal ovarian reserve test (i. e. AFC ,5-7 follicles or AMH ,0. 5 -1. 1 ng/ml).
Exclusion Criteria:
- women who suffer from any other cause of infertility other than poor ovarian reserve
- refusal of the patient to consent for using her data in the study.
Locations and Contacts
Kasr Al Aini, Cairo, Egypt
Additional Information
Starting date: July 2014
Last updated: August 8, 2015
|